Abstract
A novel imidazo-pyramidazine inhibitor of DAPK1 that undergoes class-specific interactions and extends into the substrate recognition site has been identified. This inhibitor is a good starting point for the development of selective and potent inhibitors of DAPK1, with potential use against stroke and ischemia.
Originalsprog | Engelsk |
---|---|
Tidsskrift | ChemBioChem |
Vol/bind | 16 |
Udgave nummer | 1 |
Sider (fra-til) | 59-63 |
Antal sider | 5 |
ISSN | 1439-4227 |
DOI | |
Status | Udgivet - 2 jan. 2015 |